Yanan Zhu
Stock Analyst at Wells Fargo
(0.47)
# 1,982
Out of 4,413 analysts
38
Total ratings
15.79%
Success rate
-18.55%
Average return
Main Sectors:
Top Industries:
21 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENGN enGene Holdings | Initiates: Overweight | $30 | $15.90 | +88.68% | 1 | Apr 22, 2024 | |
| AFMD Affimed | Maintains: Overweight | $30 → $25 | $5.35 | +367.29% | 2 | Apr 1, 2024 | |
| BLUE bluebird bio | Maintains: Equal-Weight | $4 → $3 | $0.89 | +238.18% | 4 | Mar 27, 2024 | |
| MGX Metagenomi | Initiates: Overweight | $25 | $7.02 | +256.13% | 1 | Mar 5, 2024 | |
| SYRE Spyre Therapeutics | Upgrades: Overweight | $12 → $35 | $33.03 | +5.96% | 1 | Mar 1, 2024 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $22 → $25 | $11.78 | +112.22% | 4 | Mar 1, 2024 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $50 | $24.13 | +107.21% | 3 | Jan 3, 2024 | |
| VYGR Voyager Therapeutics | Upgrades: Overweight | $9 → $14 | $7.82 | +79.03% | 1 | Jan 2, 2024 | |
| FATE Fate Therapeutics | Maintains: Equal-Weight | $6 → $5 | $3.95 | +26.58% | 2 | Nov 9, 2023 | |
| SGMO Sangamo Therapeutics | Maintains: Overweight | $5 → $4 | $0.51 | +676.85% | 3 | Aug 10, 2023 | |
| AVRO AVROBIO | Maintains: Overweight | $2.5 → $2 | $1.19 | +68.07% | 1 | Jul 13, 2023 | |
| TCRT Alaunos Therapeutics | Assumes: Overweight | $45 | $1.26 | +3,471.43% | 1 | Mar 27, 2023 | |
| AUTL Autolus Therapeutics | Assumes: Overweight | $8 | $3.68 | +117.39% | 1 | Mar 27, 2023 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $125 → $105 | $21.22 | +394.82% | 2 | Mar 1, 2023 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $14 → $10 | $2.43 | +311.52% | 2 | Jan 4, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $55 → $48 | $7.70 | +523.38% | 2 | Jan 4, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $135 → $120 | $21.40 | +460.75% | 1 | Jan 4, 2023 | |
| EDIT Editas Medicine | Maintains: Overweight | $50 → $36 | $5.21 | +590.98% | 3 | Jan 4, 2023 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $1.5 → $3 | $1.19 | +152.10% | 1 | Nov 14, 2022 | |
| QURE uniQure | Maintains: Equal-Weight | $34 → $24 | $4.41 | +444.22% | 1 | Aug 9, 2022 | |
| ARGX argenx SE | Maintains: Equal-Weight | n/a | $375.50 | - | 1 | Feb 2, 2021 |
enGene Holdings
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $15.90
Upside: +88.68%
Affimed
Apr 1, 2024
Maintains: Overweight
Price Target: $30 → $25
Current: $5.35
Upside: +367.29%
bluebird bio
Mar 27, 2024
Maintains: Equal-Weight
Price Target: $4 → $3
Current: $0.89
Upside: +238.18%
Metagenomi
Mar 5, 2024
Initiates: Overweight
Price Target: $25
Current: $7.02
Upside: +256.13%
Spyre Therapeutics
Mar 1, 2024
Upgrades: Overweight
Price Target: $12 → $35
Current: $33.03
Upside: +5.96%
Iovance Biotherapeutics
Mar 1, 2024
Maintains: Overweight
Price Target: $22 → $25
Current: $11.78
Upside: +112.22%
Avidity Biosciences
Jan 3, 2024
Reiterates: Overweight
Price Target: $50
Current: $24.13
Upside: +107.21%
Voyager Therapeutics
Jan 2, 2024
Upgrades: Overweight
Price Target: $9 → $14
Current: $7.82
Upside: +79.03%
Fate Therapeutics
Nov 9, 2023
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $3.95
Upside: +26.58%
Sangamo Therapeutics
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.51
Upside: +676.85%
AVROBIO
Jul 13, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $1.19
Upside: +68.07%
Alaunos Therapeutics
Mar 27, 2023
Assumes: Overweight
Price Target: $45
Current: $1.26
Upside: +3,471.43%
Autolus Therapeutics
Mar 27, 2023
Assumes: Overweight
Price Target: $8
Current: $3.68
Upside: +117.39%
Beam Therapeutics
Mar 1, 2023
Maintains: Overweight
Price Target: $125 → $105
Current: $21.22
Upside: +394.82%
Taysha Gene Therapies
Jan 4, 2023
Maintains: Overweight
Price Target: $14 → $10
Current: $2.43
Upside: +311.52%
RAPT Therapeutics
Jan 4, 2023
Maintains: Overweight
Price Target: $55 → $48
Current: $7.70
Upside: +523.38%
Intellia Therapeutics
Jan 4, 2023
Maintains: Overweight
Price Target: $135 → $120
Current: $21.40
Upside: +460.75%
Editas Medicine
Jan 4, 2023
Maintains: Overweight
Price Target: $50 → $36
Current: $5.21
Upside: +590.98%
Adaptimmune Therapeutics
Nov 14, 2022
Maintains: Equal-Weight
Price Target: $1.5 → $3
Current: $1.19
Upside: +152.10%
uniQure
Aug 9, 2022
Maintains: Equal-Weight
Price Target: $34 → $24
Current: $4.41
Upside: +444.22%
argenx SE
Feb 2, 2021
Maintains: Equal-Weight
Price Target: n/a
Current: $375.50
Upside: -